Phytosterols protect against diet-induced hypertriglyceridemia in Syrian golden hamsters

Lipids Health Dis. 2014 Jan 6:13:5. doi: 10.1186/1476-511X-13-5.

Abstract

Background: In addition to lowering LDL-C, emerging data suggests that phytosterols (PS) may reduce blood triglycerides (TG), however, the underlying mechanisms are not known.

Methods: We examined the TG-lowering mechanisms of dietary PS in Syrian golden hamsters randomly assigned to a high fat (HF) diet or the HF diet supplemented with PS (2%) for 6 weeks (n = 12/group). An additional subset of animals (n = 12) was provided the HF diet supplemented with ezetimibe (EZ, 0.002%) as a positive control as it is a cholesterol-lowering agent with known TG-lowering properties.

Results: In confirmation of diet formulation and compound delivery, both the PS and EZ treatments lowered (p < 0.05) intestinal cholesterol absorption (24 and 31%, respectively), blood non-HDL cholesterol (61 and 66%, respectively), and hepatic cholesterol (45 and 55%, respectively) compared with the HF-fed animals. Blood TG concentrations were lower (p < 0.05) in the PS (49%) and EZ (68%)-treated animals compared with the HF group. The TG-lowering response in the PS-supplemented group was associated with reduced (p < 0.05) intestinal SREBP1c mRNA (0.45 fold of HF), hepatic PPARα mRNA (0.73 fold of HF), hepatic FAS protein abundance (0.68 fold of HD), and de novo lipogenesis (44%) compared with the HF group. Similarly, lipogenesis was lower in the EZ-treated animals, albeit through a reduction in the hepatic protein abundance of ACC (0.47 fold of HF).

Conclusions: Study results suggest that dietary PS are protective against diet-induced hypertriglyceridemia, likely through multiple mechanisms that involve modulation of intestinal fatty acid metabolism and a reduction in hepatic lipogenesis.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anticholesteremic Agents / pharmacology*
  • Anticholesteremic Agents / therapeutic use
  • Azetidines / pharmacology
  • Azetidines / therapeutic use
  • Cholesterol, HDL / blood
  • Cricetinae
  • Diet, High-Fat / adverse effects
  • Drug Evaluation, Preclinical
  • Ezetimibe
  • Fatty Acids / metabolism
  • Gene Expression / drug effects
  • Hypertriglyceridemia / blood
  • Hypertriglyceridemia / drug therapy*
  • Hypertriglyceridemia / etiology
  • Intestinal Absorption / drug effects
  • Intestine, Small / drug effects
  • Intestine, Small / metabolism
  • Lipogenesis
  • Liver / drug effects
  • Liver / metabolism
  • Male
  • Mesocricetus
  • Phytosterols / pharmacology*
  • Phytosterols / therapeutic use
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Sterol Regulatory Element Binding Protein 1 / genetics
  • Sterol Regulatory Element Binding Protein 1 / metabolism

Substances

  • Anticholesteremic Agents
  • Azetidines
  • Cholesterol, HDL
  • Fatty Acids
  • Phytosterols
  • RNA, Messenger
  • Srebf1 protein, mouse
  • Sterol Regulatory Element Binding Protein 1
  • Ezetimibe